Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02188758
Recruitment Status : Completed
First Posted : July 14, 2014
Last Update Posted : March 13, 2018
Sponsor:
Collaborator:
MaineHealth
Information provided by (Responsible Party):
Alex H. Gifford, Dartmouth-Hitchcock Medical Center

Brief Summary:
The goal of this study is to identify chemical compounds in the blood and sputum (i.e., biomarkers) that are associated with objective measurements of health status in patients with cystic fibrosis (CF). This study builds upon observations that blood levels of hepcidin-25, a protein that regulates how the body uses and stores iron, vary during CF pulmonary exacerbation (CFPE).

Condition or disease Intervention/treatment
Cystic Fibrosis Other: Adults - CFPE Treatment

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment Responses?
Actual Study Start Date : July 2014
Actual Primary Completion Date : December 2017
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Adults - CFPE Treatment
Other: CF Pulmonary Exacerbation (CFPE) Treatment
Other: Adults - CFPE Treatment
Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.




Primary Outcome Measures :
  1. Change in Serum Hepcidin-25 Concentration After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    The primary endpoint of this study is the characterization of 3 groups (i.e., "low," "intermediate," and "high") of serum hepcidin-25 responders to CFPE treatment. Response will be defined as the ratio of post- to pre-treatment serum hepcidin-25 concentration for each subject.


Secondary Outcome Measures :
  1. Change in Percent-Predicted Forced Expiratory Volume in One Second (FEV1%) After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for FEV1% for each subject.

  2. Change in Body Mass Index (BMI) After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for BMI for each subject.

  3. Change in CFRSD-CRISS Score After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    CFRSD-CRISS is a patient-reported outcome (PRO) instrument developed by the Seattle Quality of Life Group at the University of Washington and used herein under license to evaluate the severity of symptoms of CF in adults and adolescents (≥12 years) with a chronic respiratory infection. Symptoms assessed in the CFRSD-CRISS are: difficulty breathing, cough, cough up mucus, chest tightness, wheeze, feeling feverish, tired, and chills/sweats. The 8 items quantify symptom severity for the previous 24 hours to capture the magnitude of symptoms in stable CF, during medically treated CF exacerbations, and during recovery from an exacerbation. We will determine the within-subject differences in CFRSD-CRISS score associated with CFPE treatment.

  4. Change in Serum Iron After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for serum iron concentration for each subject.

  5. Change in Serum Interleukin-6 (IL-6) Concentration After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for serum interleukin-6 (IL-6) concentration for each subject.

  6. Change in Sputum Iron Content After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for sputum iron content for each subject.

  7. Change in Serum EPO Concentration After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for serum erythropoietin (EPO) for each subject.

  8. Change in Transferrin Saturation After Hospitalization for CF Pulmonary Exacerbation Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for transferrin saturation for each subject.

  9. Change in Serum TREM-1 Concentration After Hospitalization for CF Pulmonary Exacerbation Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for serum triggering receptor expressed on myeloid cells-1 (TREM-1) for each subject.

  10. Change in Serum sIL-6R Concentration After Hospitalization for CF Pulmonary Exacerbation Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for serum soluble IL-6 receptor (sIL-6R) concentration for each subject.

  11. Change in Hemoglobin Concentration After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for serum hemoglobin concentration for each subject.


Other Outcome Measures:
  1. Change in Sputum SDI After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratio for Simpson Diversity Index (SDI) for each subject.

  2. Change in Sputum Pseudomonas aeruginosa Gene Expression After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratios for selected Pseudomonas aeruginosa mRNA transcript levels.

  3. Change in Peripheral Blood Mononuclear Cell (PBMC) Gene Expression After Hospitalization for CF Pulmonary Exacerbation (CFPE) Treatment [ Time Frame: Duration of hospitalization, an expected average of 12 days ]
    Post- to pre-treatment ratios for selected mRNA transcript levels.


Biospecimen Retention:   Samples With DNA
Bacterial DNA and RNA will be isolated from sputum samples and stored for future analyses.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients greater than
Criteria

Inclusion Criteria (required at screening visit):

  • Diagnosis of CF confirmed by history of positive chloride sweat test and/or CFTR mutation analysis;
  • History of consistent sputum production on most occasions;
  • FEV1% greater than or equal to 75% of best measurement in previous 6 months;
  • 1 or more hospitalizations for CFPE treatment with intravenous antibiotics within the previous year;
  • Absence of CFPE (i.e., Akron Pulmonary Exacerbation Score <5);
  • Not admitted to hospital within the previous 3 weeks;
  • Body weight greater than or equal to 75% of best measurement in previous 6 months;
  • Provision of signed informed-consent to study protocol;
  • 18<Age>65

Exclusion Criteria:

  • Women who are pregnant or lactating;
  • Subject does not meet Inclusion criteria;
  • Recent and/or persistent visible blood in sputum (hemoptysis);
  • Rescue use of oral antibiotics within the previous 3 weeks, defined as antibiotic use for health deterioration rather than chronic suppression

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02188758


Locations
Layout table for location information
United States, Maine
Maine Medical Center
South Portland, Maine, United States, 04106
United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
MaineHealth
Publications:
Layout table for additonal information
Responsible Party: Alex H. Gifford, Associate Professor of Medicine, Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT02188758    
Other Study ID Numbers: D14136
KL2TR001088 ( U.S. NIH Grant/Contract )
First Posted: July 14, 2014    Key Record Dates
Last Update Posted: March 13, 2018
Last Verified: March 2018
Keywords provided by Alex H. Gifford, Dartmouth-Hitchcock Medical Center:
iron
hepcidin-25
pulmonary exacerbation
interleukin-6
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pulmonary Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases